MARK4 (microtubule affinity-regulating kinase 4), also known as PAR-1 homolog or C-TAK1. is a serine/threonine kinase belonging to the AMPK-related kinase family. It plays a critical role in regulating microtubule dynamics, cell polarity, and intracellular signaling pathways. Structurally, MARK4 contains a catalytic kinase domain, a ubiquitin-associated (UBA) domain, and a spacer region that modulates substrate interactions. Notably, it phosphorylates microtubule-associated proteins (e.g., tau, MAP2/4) to destabilize microtubules, influencing cell division, neuronal development, and organelle transport.
Research highlights its involvement in pathological conditions. Hyperphosphorylation of tau by MARK4 contributes to neurofibrillary tangle formation in Alzheimer’s disease. It also interacts with pathways like Wnt/β-catenin and mTOR, linking it to cancer progression, metabolic disorders, and autophagy dysregulation. MARK4 overexpression has been observed in several cancers, promoting metastasis and chemoresistance.
MARK4 antibodies are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate MARK4's role in diseases. Recent studies explore MARK4 inhibitors as potential therapeutics, emphasizing the antibody's diagnostic and research relevance. Its dual role in neurodegeneration and oncology makes MARK4 a compelling target for interdisciplinary biomedical research.